High Mortality Risk of Hemorrhagic Stroke with Warfarin After Mechanical Valve Replacement, Finds Study
Bangladesh: Researchers have found in a new study that hemorrhagic stroke (HS) occurred in 4.4% of Bangladeshi patients after mechanical heart valve replacement (m-HVR) and was associated with a high mortality rate of 52%. Severe pulmonary hypertension increased the risk of HS by 4.4 times, while warfarin therapy extending beyond 104 months nearly doubled the risk. The findings highlight the need for long-term anticoagulation monitoring and population-specific risk assessment, particularly in South Asian patients with genetic variations influencing warfarin metabolism.
The findings are from the Multidimensional Approach of Genotype and Phenotype In Stroke Etiology (MAGPIE) study, led by Dipannita Adhikary and colleagues at Royal Holloway University of London, and published in IBrain. This ambispective study included 568 patients in Bangladesh who had undergone heart valve replacement and were on long-term warfarin therapy for at least six months between 2010 and 2024.
The study revealed the following findings:
- Hemorrhagic stroke affected a small but clinically important proportion of patients, with over half of these cases resulting in death.
- The median age of affected patients was 40 years, indicating a significant impact on the working-age population.
- Duration of warfarin therapy varied by procedure, with the longest exposure seen in patients undergoing double valve replacement compared to single valve replacement or combined coronary artery bypass grafting.
- A threshold of 104 months of warfarin therapy was identified as a key point beyond which the risk of hemorrhagic stroke increased significantly.
- Patients receiving anticoagulation for ≥104 months had a higher likelihood of developing hemorrhagic stroke.
- Severe pulmonary hypertension was identified as an independent predictor, markedly increasing the risk of hemorrhagic stroke.
- A high prevalence of the VKORC1 gene variant in Bangladeshi populations may influence warfarin metabolism.
- This genetic variation may contribute to differences in drug response and bleeding risk.
- The findings highlight the need for individualized anticoagulation strategies, particularly in South Asian populations.
The study has some limitations. As a single-centre observational analysis, its findings may have limited generalizability. The absence of real-time INR values at the time of hemorrhagic stroke restricts direct assessment of anticoagulation levels, and unmeasured factors such as medication adherence, socioeconomic status, and healthcare access may have influenced outcomes.
The authors suggest that anticoagulation care should extend beyond short-term monitoring. Strengthening long-term follow-up and establishing dedicated anticoagulation clinics could help reduce complications, as prior evidence has shown improved outcomes through structured care models.
Overall, the findings highlight the importance of continuous monitoring, patient education, and individualized risk assessment following mechanical heart valve replacement. Tailoring anticoagulation strategies based on therapy duration, comorbidities, and genetic factors may help improve outcomes and reduce serious complications.
Reference:
Adhikary, D., Yusuf, M. A., Parvez, A. N., B. Faruque, S. M., Barman, S., Moureen, A., Rogers, L. J., Momin, A., Chandrasekaran, V., Adhikary, A. B., & Ranjan, R. Risk of hemorrhagic stroke in warfarin-treated patients following heart valve replacement: Findings from the MAGPIE study. Ibrain. https://doi.org/10.1002/ibra.70020
Next Story